Precursor T-lymphoblastic lymphoma in a patient after successful treatment of acute promyelocytic leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A10224437" target="_blank" >RIV/61989592:15110/09:10224437 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Precursor T-lymphoblastic lymphoma in a patient after successful treatment of acute promyelocytic leukemia
Original language description
Introduction: Acute promyelocytic leukemia (APL) is a relatively rare subtype of acute myeloid leukemia. It has become the best curable subtype of acute leukemias in adults due to the inclusion of all-trans-retinoic acid (ATRA) in the treatment. Despitethe efficacy of ATRA, chemotherapy must be added in APL patients in order to maintain durable complete remission. However, chemotherapy administration is inevitably related to many complications, including the risk of secondary malignancies. T-lymphoblastic lymphoma (T-LBL) is an infrequent disease that belongs to highly aggressive lymphomas group. Case report: The authors describe a 25-year-old woman treated for APL in 2002 and developed precursor T-LBL five years later. Conclusion: Several cases of secondary acute lymphoblastic leukemias in ?cured? APL patients have been described, but probably no patient with secondary precursor T-LBL. Secondary malignancies has become one of the topics discussed (not only) in APL patients. It is app
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)